Clinical Trials Browser

Phase 3 × INDUSTRY × belantamab mafodotin × Clear all

NCT04246047 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT06868654 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

72 enrolled 10 charts

Multiple Myeloma

NCT06868667 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT06679101 2026-04-22

DREAMM-10

Phase 3 Recruiting

Multiple Myeloma

NCT04162210 2026-03-31

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Multiple Myeloma

NCT04549363 2023-12-13

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Phase 3 Terminated

16 enrolled 7 charts

Multiple Myeloma